Example：10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies Nature Medicine (IF53.44), Pub Date : 2021-11-11, DOI: 10.1038/s41591-021-01565-6 Sheng Fu, Sheldon E. Litwin, Ryan J. Tedford
SGLT-2 inhibitors show promise for treatment of heart failure with preserved ejection fraction, but clinical data are nuanced. Appropriate endpoint selection will be key to deciphering their benefits.